1-(benzo-1,4-dioxan-2-ylmethyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid methyl ester | 113770-98-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 1-(benzo-1,4-dioxan-2-ylmethyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid methyl ester
• 英文别名: methyl 1-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3,6-dihydro-2H-pyridine-5-carboxylate
• CAS: 113770-98-2
• 化学式: C₁₆H₁₉NO₄
• 分子量: 289.331
• InChiKey: SXOXDIMPTJTXNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(benzo-1,4-dioxan-2-ylmethyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid methyl ester 、 盐酸 生成 1-(benzo-1,4-dioxan-2-ylmethyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid methyl ester hydrochloride
  参考文献：
  名称：

  FROSTL, WOLFGANG

  摘要：

  DOI：
• 作为产物：
  描述：

  去甲槟榔碱氢溴酸盐 、 2-溴甲基-1,4-苯并二噁烷 以74%的产率得到
  参考文献：
  名称：

  FROSTL, WOLFGANG

  摘要：

  DOI：

文献信息

• [EN] 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES<br/>[FR] DÉRIVÉS DE 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMÉTHYLE UTILISÉS EN TANT QU'ANTAGONISTES DES ALPHA2C POUR TRAITER DES MALADIES DES SYSTÈMES NERVEUX PÉRIPHÉRIQUE ET CENTRAL
  申请人：ORION CORP

  公开号：WO2009013390A1

  公开（公告）日：2009-01-29

  Compounds of formula (I), wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases and conditions of the peripheric system and the central nervous system (CNS).

  式(I)的化合物，其中X、Z、R1-R4和m如权利要求中所定义，具有α2C拮抗活性，因此可用于治疗外周系统和中枢神经系统（CNS）的疾病和症状。
• Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US04957928A1

  公开（公告）日：1990-09-18

  The invention relates to novel hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds of formula ##STR1## in which the variable R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, alk, X, Z, m, n and p, the dotted line and the substituents of the ring A have the meanings indicated in the specification and in the claims, and to their tautomers and/or salts. These compounds can be used as pharmaceutical active ingredients and can be prepared in a manner known per se.

  该发明涉及一种新型的氢化1-苯氧基环氧烷基吡啶羧酸化合物，其化学结构如下：在该结构中，变量R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, alk, X, Z, m, n和p，虚线和环A的取代基具有规范和索赔中指示的含义，以及它们的互变异构体和/或盐。这些化合物可以用作药用活性成分，并且可以按照已知的方法制备。
• Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds and
  申请人：Ciba-Geigy Corporation

  公开号：US05112855A1

  公开（公告）日：1992-05-12

  The invention relates to novel hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds of formula ##STR1## in which the variables R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, alk, X, Z, m, n and p, the dotted line and the substituents of the ring A have the meanings indicated in the specification and in the claims, and to their tautomers and/or salts. These compounds can be used as pharmaceutical active ingredients and can be prepared in a manner known per se.

  本发明涉及一种新型氢化的1-苯氧环烷基吡啶羧酸化合物，其化学式为##STR1## 其中变量R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5、alk、X、Z、m、n和p、虚线和环A的取代基在说明书和权利要求书中具有所指示的含义，以及它们的互变异构体和/或盐。这些化合物可以用作药物活性成分，并可以按照已知方法制备。
• 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES
  申请人：Din Belle David

  公开号：US20120035210A9

  公开（公告）日：2012-02-09

  Compounds of formula I wherein X, Z, R 1 -R 4 , and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.

  式I的化合物，其中X、Z、R1-R4和m如权利要求所定义，表现出α2C拮抗活性，因此可用作α2C拮抗剂。还公开了治疗外周系统和中枢神经系统疾病和病症的方法。
• 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES
  申请人：ORION CORPORATION

  公开号：US20130281486A1

  公开（公告）日：2013-10-24

  Compounds of formula I wherein X, Z, R 1 -R 4 , and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.

  式(I)的化合物，其中X、Z、R1-R4和m如权利要求中所定义，表现出α2C拮抗活性，因此可用作α2C拮抗剂。还公开了治疗外周系统和中枢神经系统疾病和病况的方法。